Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure
Top Cited Papers
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca Canada Inc
This publication has 36 references indexed in Scilit:
- Similarities and Distinctions Between Acetazolamide and Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Acute Heart Failure: Key Insights Into ADVOR and EMPULSEEuropean Journal of Heart Failure, 2023
- Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the USJAMA Cardiology, 2023
- Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2022
- Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart FailureJournal of Cardiac Failure, 2021
- Decongestion discriminates risk for one‐year mortality in patients with improving renal function in acute heart failureEuropean Journal of Heart Failure, 2021
- Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trialAmerican Heart Journal, 2021
- Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failureEuropean Journal of Heart Failure, 2020
- Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)European Journal of Heart Failure, 2020
- Evaluation of Kidney Function Throughout the Heart Failure Trajectory – A Position Statement from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2020
- The Use of Diuretics in Heart Failure with Congestion — A Position Statement from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2019